论文部分内容阅读
[目的]分析放疗对于Ⅳ期非小细胞肺癌(NSCLC)患者预后的影响。[方法]对459例接受放疗的Ⅳ期NSCLC患者资料进行回顾性分析。放疗均采用6/10MVX线直线加速器,全脑和骨放疗为2周10次共30Gy的分割方案。原发灶、区域淋巴结中位放疗剂量为52Gy(25～66Gy)。[结果]459例患者中位生存期10.7个月。1、2、3、4、5年生存率分别为43%、17%、8%、5%、3%。年龄<70岁较年龄≥70岁的中位生存期长(11.4个月与9.0个月,P=0.043)。单器官转移比多器官转移的中位生存期长(10.9个月与8.6个月,P=0.017)。有无脑转移的中位生存期为9.6个月与11.4个月(P<0.001)。化疗比未化疗的中位生存期长(10.9个月与8.6个月,P=0.011)。原发灶放疗比未行原发灶放疗的中位生存期长(10.9个月与10.3个月,P=0.047)。性别、病理类型对生存未见显著影响。[结论]年龄、是否脑转移、转移器官数目、是否化疗及是否原发灶放疗对Ⅳ期NSCLC放疗后生存有显著影响。
[Objective] To analyze the influence of radiotherapy on the prognosis of stage Ⅳ non-small cell lung cancer (NSCLC). [Methods] The data of 459 NSCLC patients undergoing radiotherapy were retrospectively analyzed. Radiotherapy were used 6 / 10MVX line linear accelerator, whole brain and bone radiotherapy for 10 weeks 2 times a total of 30Gy segmentation scheme. The primary tumor, regional lymph node median dose of 52Gy (25 ~ 66Gy). [Results] The median survival time in 459 patients was 10.7 months. The 1, 2, 3, 4, 5-year survival rates were 43%, 17%, 8%, 5%, 3% respectively. Median survival was longer in patients <70 years of age and older than 70 years (11.4 and 9.0 months, P = 0.043). Single organ metastases had a longer median survival than multiple organ metastases (10.9 months vs 8.6 months, P = 0.017). The median survival with or without brain metastases was 9.6 months and 11.4 months (P <0.001). Chemotherapy had a longer median survival than non-chemotherapy (10.9 months vs 8.6 months, P = 0.011). The median survival was longer in primary tumors than in primary tumors (10.9 and 10.3 months, P = 0.047). Gender, pathological type had no significant effect on survival. [Conclusion] Age, brain metastasis, number of metastatic organs, whether chemotherapy and whether primary tumor radiotherapy have significant effect on survival after radiotherapy for stage IV NSCLC.